Silexion Therapeutics Ltd.
SLXNHealthcare|Biotechnology|IL
$0.15
+0.00 (+0.97%)
DCF Value
$35.88
Tangible Book / Share
$0.06
Cash / Share
$3.24
Financials
Financial Snapshot
Market Cap
$60.8K
Enterprise Value
-$758.2K
Revenue (TTM)
$0.00
Net Income (TTM)
-$14.0M
Cash & Investments
$2.2M
Net Cash
$819.0K
Free Cash Flow (TTM)
-$12.4M
Operating CF (TTM)
-$12.4M
Debt/Equity
32.05
Cash Runway & Burn Rate
Cash on Hand
$2.2M
Quarterly Burn
$3.1M
Monthly Burn
$1.0M
Est. Runway
~0.7 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $51.7K | $38.9K | $8.3M | $4.6M | $1.2M | $6.0M | $2.2M | |
| Operating Cash Flow | -$75.0K | -$1.4M | -$3.3M | -$4.5M | -$8.4M | -$10.8M | -$12.4M | |
| Free Cash Flow | -$75.0K | -$1.4M | -$3.4M | -$4.5M | -$8.4M | -$10.8M | -$12.4M | |
| Capital Expenditure | $0.00 | -$4.00 | -$40.0K | -$12.0K | -$22.0K | -$9.0K | -$2.0K | |
| Financing Cash Flow | $126.7K | $116.4M | $2.8M | $522.0K | $5.1M | $15.6M | $11.2M |
R&D Spending
R&D (TTM)
$9.1M
R&D Intensity
—
R&D Growth vs Prior
+27.6%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $0.00 | $3.2M | $3.7M | $5.8M | $7.1M | $9.1M | |
| SG&A | $195.9K | $943.9K | $577.0K | $928.0K | $6.7M | $4.5M | $5.0M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $9.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$9.0K | |
| R&D | $0.00 | $0.00 | $3.2M | $3.7M | $5.8M | $7.1M | $9.1M | |
| SG&A | $195.9K | $943.9K | $577.0K | $928.0K | $6.7M | $4.5M | $5.0M | |
| Operating Income | -$195.9K | -$943.9K | -$3.9M | -$4.7M | -$12.6M | $11.6M | $9.1M | |
| Interest Expense | $0.00 | $0.00 | $85.0K | $9.0K | $52.0K | $13.0K | $6.0K | |
| Pretax Income | -$195.9K | -$755.2K | -$3.5M | -$5.1M | -$16.5M | -$11.9M | -$14.0M | |
| Net Income | -$195.9K | -$755.2K | -$3.2M | -$4.9M | -$16.4M | -$11.9M | -$14.0M | |
| EPS (Diluted) | -17.79 | -68.63 | 52.37 | -6634.98 | -3953.62 | -89.60 | -56.54 | |
| EBITDA | -$195.9K | -$755.0K | -$3.3M | -$5.0M | -$16.5M | -$11.9M | -$14.1M | |
| Shares Out. (M) | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.13 | 0.69 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $51.7K | $38.9K | $8.3M | $4.6M | $1.2M | $6.0M | $2.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $51.7K | $407.8K | $8.8M | $5.0M | $2.3M | $6.6M | $3.7M | |
| Total Assets | $129.4K | $115.4M | $9.3M | $5.3M | $2.9M | $7.2M | $4.2M | |
| Total Current Liabilities | $29.4K | $348.6K | $1.6M | $2.2M | $3.5M | $2.8M | $4.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $3.0M | $286.0K | $0.00 | |
| Total Liabilities | $299.4K | $508.9K | $16.4M | $17.3M | $6.9M | $4.6M | $4.2M | |
| Stockholders' Equity | -$170.0K | $114.9M | -$10.7M | -$15.5M | -$4.0M | $2.6M | $44.0K | |
| Retained Earnings | -$195.9K | -$951.1K | -$21.9M | -$26.8M | -$43.3M | -$55.2M | -$61.5M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$75.0K | -$1.4M | -$3.3M | -$4.5M | -$8.4M | -$10.8M | -$12.4M | |
| Capital Expenditure | $0.00 | -$4.00 | -$40.0K | -$12.0K | -$22.0K | -$9.0K | -$2.0K | |
| Free Cash Flow | -$75.0K | -$1.4M | -$3.4M | -$4.5M | -$8.4M | -$10.8M | -$12.4M | |
| Investing Cash Flow | $0.00 | $0.00 | -$524.0K | $573.0K | -$22.0K | -$14.0K | -$8.0K | |
| Financing Cash Flow | $126.7K | $116.4M | $2.8M | $522.0K | $5.1M | $15.6M | $11.2M | |
| Issuance of Stock | -$23.3K | $118.8M | $0.00 | $0.00 | $3.1M | $16.3M | $11.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $150.0K | $150.0K | $0.00 | $0.00 | -$250.0K | -$696.0K | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $125.0K | $130.0K | $5.9M | $134.0K | $580.0K | |
| Net Change in Cash | $51.7K | -$12.8K | -$1.8M | -$3.7M | -$3.4M | $4.8M | -$1.2M |
Dilution Tracker
Shares outstanding grew 1108.3% over 5 years — significant dilution
Shares Outstanding
0M
5-Year Share Growth
+1108.3%
Stock Issuance (TTM)
$11.4M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.13 | 0.69 | |
| Change vs Prior % | — | 0.0% | 1.3% | -93.3% | 458.1% | 3097.5% | 417.0% | |
| Stock Issuance | -$23.3K | $118.8M | $0.00 | $0.00 | $3.1M | $16.3M | $11.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $125.0K | $130.0K | $5.9M | $134.0K | $580.0K |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | 115.2% | -0.7% | 30.1% | 31.9% | 412.2% | -457.6% | -563.1% | |
| ROA % | -151.4% | -0.7% | -34.4% | -94.0% | -574.3% | -165.1% | -328.7% | |
| ROIC % | -195.9% | -0.8% | -49.2% | -147.6% | -2504.2% | 250.7% | 628.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -381.9% | -308.9% | -21.3% | -168.6% | 192.5% | |
| Net Income | 0.0% | -285.6% | -325.7% | -53.7% | -232.7% | 27.6% | |
| EPS (Diluted) | 0.0% | -285.8% | 176.3% | -12769.4% | 40.4% | 97.7% | |
| Operating Cash Flow | 0.0% | -1776.3% | -137.0% | -35.8% | -85.4% | -28.9% | |
| Free Cash Flow | 0.0% | -1776.3% | -139.8% | -34.5% | -85.4% | -28.6% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 14.9% | 56.8% | 22.8% | |
| SG&A Expense | 0.0% | 381.9% | -38.9% | 60.8% | 625.3% | -33.5% | |
| Total Assets | 0.0% | 89092.5% | -91.9% | -43.7% | -45.5% | 152.0% | |
| Book Value / Share | 0.0% | 67694.9% | -106.1% | -2449.1% | 94.1% | 102.0% | |
| Debt | 0.0% | 0.0% | 0.0% | -36.9% | 2526.3% | -89.6% | |
| Diluted Shares | 0.0% | 0.0% | 1.3% | -93.3% | 458.1% | 3097.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B2.27
EV/EBITDA0.05
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$35.88
Tangible Book / Share
$0.06
Cash / Share
$3.24
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -147.98 | -38.36 | 50.27 | -0.40 | -0.08 | -0.21 | -0.00 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -170.39 | 0.25 | -2.75 | -0.13 | -0.31 | 0.98 | 2.27 | |
| EV/EBITDA | -147.62 | -38.31 | -6.43 | 0.49 | -0.28 | 0.25 | 0.05 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-31.26
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$6.2M | -$2.4M | -$2.3M |
| EPS | $-47.00 | $-18.40 | $-17.50 |
| # Analysts (EPS) | 1 | 1 | 1 |